Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)
Conditions
Interventions
Azacitidine
Physician Choice
Locations
108
United States
University of Alabama School of Medicine
Birmingham, Alabama, United States
Indiana University Cancer Center
Indianapolis, Indiana, United States
Washington University School of Medicine
St Louis, Missouri, United States
Mount Sinai Medical Center
New York, New York, United States
Case Western Reserve University
Cleveland, Ohio, United States
Oregon Cancer Center
Portland, Oregon, United States
Start Date
November 1, 2003
Primary Completion Date
July 1, 2007
Completion Date
July 1, 2007
Last Updated
October 29, 2019
NCT07270978
NCT05292664
NCT06499285
NCT04953897
NCT04953910
NCT05350748
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions